Janusz Rak

List of Publications by Year in Descending Order

107 papers	7,126 citations	42 h-index	84 g-index
109 ext. papers	8,276 ext. citations	8.3 avg, IF	6.15 L-index

#	Paper	IF	Citations
107	Coagulome and the tumor microenvironment: an actionable interplay.. *Trends in Cancer*, **2022**,	12.5	5
106	Cancer genetic alterations and risk of venous thromboembolism. *Thrombosis Research*, **2022**, 213, S29-S34	3.2	0
105	Blood coagulation and cancer genes. *Best Practice and Research in Clinical Haematology*, **2022**, 101349	4.2	0
104	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. *Blood Advances*, **2021**, 5, 1682-1694	7.8	13
103	Cancer genes and blood clots. *Blood*, **2021**, 137, 1996-1997	2.2	1
102	Nanofluidics for Simultaneous Size and Charge Profiling of Extracellular Vesicles. *Nano Letters*, **2021**, 21, 4895-4902	11.5	3
101	Oncogenic RAS drives the CRAF-dependent extracellular vesicle uptake mechanism coupled with metastasis. *Journal of Extracellular Vesicles*, **2021**, 10, e12091	16.4	5
100	Plasmonic nanobowtiefluidic device for sensitive detection of glioma extracellular vesicles by Raman spectrometry. *Lab on A Chip*, **2021**, 21, 855-866	7.2	16
99	Extracellular Vesicle Mediated Vascular Pathology in Glioblastoma. *Sub-Cellular Biochemistry*, **2021**, 97, 247-273	5.5	2
98	Selection of Fluorescent, Bioluminescent, and Radioactive Tracers to Accurately Reflect Extracellular Vesicle Biodistribution. *ACS Nano*, **2021**, 15, 3212-3227	16.7	31
97	Isolation of Extracellular Vesicles for Proteomic Profiling. *Methods in Molecular Biology*, **2021**, 2261, 193-206	1.4	5
96	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca flux to mitochondria. *Nature Communications*, **2021**, 12, 5404	17.4	3
95	Extracellular Vesicle Proteomes Shed Light on the Evolutionary, Interactive, and Functional Divergence of Their Biogenesis Mechanisms. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 734950	5.7	1
94	Human multipotent mesenchymal stromal cells cytokine priming promotes RAB27B-regulated secretion of small extracellular vesicles with immunomodulatory cargo. *Stem Cell Research and Therapy*, **2020**, 11, 539	8.3	13
93	Extracellular vesicles from genetically unstable, oncogene-driven cancer cells trigger micronuclei formation in endothelial cells. *Scientific Reports*, **2020**, 10, 8532	4.9	10
92	SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors. *Journal of Pathology*, **2020**, 252, 77-87	9.4	6
91	Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. *Cancers*, **2020**, 12,	6.6	11

90	L(C3)icensing of exosomes for RNA export. *Nature Cell Biology*, **2020**, 22, 137-139	23.4	3
89	A reference map of the human binary protein interactome. *Nature*, **2020**, 580, 402-408	50.4	269
88	Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations. *Thrombosis Research*, **2020**, 191 Suppl 1, S99-S105	8.2	8
87	Mapping Subpopulations of Cancer Cell-Derived Extracellular Vesicles and Particles by Nano-Flow Cytometry. *ACS Nano*, **2019**, 13, 10499-10511	16.7	76
86	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nature Communications*, **2019**, 10, 558	17.4	42
85	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. *Nature Communications*, **2019**, 10, 557	17.4	72
84	Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis. *Seminars in Thrombosis and Hemostasis*, **2019**, 45, 373-384	5.3	19
83	Leukobiopsy - A Possible New Liquid Biopsy Platform for Detecting Oncogenic Mutations. *Frontiers in Pharmacology*, **2019**, 10, 1608	5.6	3
82	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 431-497	5.1	5
81	Oncogenic Regulation of Extracellular Vesicle Proteome and Heterogeneity. *Proteomics*, **2019**, 19, e1800189	4.8	19
80	Age-related variations in gene expression patterns of renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 166-175	2.8	4
79	Molecular subtypes and differentiation programmes of glioma stem cells as determinants of extracellular vesicle profiles and endothelial cell-stimulating activities. *Journal of Extracellular Vesicles*, **2018**, 7, 1490144	16.4	30
78	The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells. *Molecular and Cellular Proteomics*, **2018**, 17, 1948-1964	7.6	72
77	Cell Surface GRP78: A Novel Regulator of Tissue Factor Procoagulant Activity **2018**, 63-85		2
76	Single cell coagulomes as constituents of the oncogene-driven coagulant phenotype in brain tumours. *Thrombosis Research*, **2018**, 164 Suppl 1, S136-S142	8.2	13
75	Extracellular Vesicles as Conduits of Non-Coding RNA Emission and Intercellular Transfer in Brain Tumors. *Non-coding RNA*, **2018**, 5,	7.1	23
74	Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. *Neuro-Oncology*, **2018**, 20, 236-248	1	64
73	Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumor-derived extracellular vesicles. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 1800-1813	15.4	32

72	Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation. *Seminars in Cell and Developmental Biology*, **2017**, 67, 11-22	7.5	81
71	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. *Journal of Biological Chemistry*, **2017**, 292, 21180-21192	5.4	11
70	Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile. *Biochemical and Biophysical Research Communications*, **2017**, 494, 700-705	3.4	8
69	Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix. *Oncotarget*, **2017**, 8, 105383-105396	3.3	1
68	Comparative transcriptomic analysis of human and Drosophila extracellular vesicles. *Scientific Reports*, **2016**, 6, 27680	4.9	29
67	Extracellular Vesicles in Brain Tumor Progression. *Cellular and Molecular Neurobiology*, **2016**, 36, 383-407	4.6	54
66	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment. *American Journal of Pathology*, **2016**, 186, 446-59	5.8	28
65	PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells. *Angiogenesis*, **2016**, 19, 25-38	10.6	30
64	Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras. *Oncotarget*, **2016**, 7, 51991-52002	3.3	57
63	Oncosomes - large and small: what are they, where they came from?. *Journal of Extracellular Vesicles*, **2016**, 5, 33109	16.4	97
62	Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy. *Thrombosis Research*, **2016**, 140 Suppl 1, S37-43	8.2	12
61	Studies on the Tumor Vasculature and Coagulant Microenvironment. *Methods in Molecular Biology*, **2016**, 1458, 39-58	1.4	2
60	Extracellular vesicles in the biology of brain tumour stem cells--Implications for inter-cellular communication, therapy and biomarker development. *Seminars in Cell and Developmental Biology*, **2015**, 40, 17-26	7.5	74
59	Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content. *Journal of Biological Chemistry*, **2015**, 290, 24534-46	5.4	76
58	Cancer: Organ-seeking vesicles. *Nature*, **2015**, 527, 312-4	50.4	28
57	Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle. *Scientific Reports*, **2015**, 5, 8717	4.9	48
56	Oncogene-dependent survival of highly transformed cancer cells under conditions of extreme centrifugal force - implications for studies on extracellular vesicles. *Cellular and Molecular Biology Letters*, **2015**, 20, 117-29	8.1	2
55	An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum. *Nature Chemistry*, **2015**, 7, 569-75	17.6	198

54	Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day. *Journal of Extracellular Vesicles*, **2015**, 4, 26901	16.4	57
53	The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis. *Biochemical and Biophysical Research Communications*, **2014**, 454, 262-8	3.4	16
52	Ageing-related responses to antiangiogenic effects of sunitinib in atherosclerosis-prone mice. *Mechanisms of Ageing and Development*, **2014**, 140, 13-22	5.6	8
51	Oncogenic ras-driven cancer cell vesiculation leads to emission of double-stranded DNA capable of interacting with target cells. *Biochemical and Biophysical Research Communications*, **2014**, 451, 295-301	3.4	123
50	Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 3544-9	11.5	78
49	Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer. *Thrombosis Research*, **2014**, 133 Suppl 2, S1-9	8.2	44
48	Genetic basis of thrombosis in cancer. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, 284-95	5.3	15
47	Brain neoplasms and coagulation-lessons from heterogeneity. *Rambam Maimonides Medical Journal* , **2014**, 5, e0030	1.8	8
46	Qualitative changes in the proteome of extracellular vesicles accompanying cancer cell transition to mesenchymal state. *Experimental Cell Research*, **2013**, 319, 2747-57	4.2	64
45	Impact of host ageing on the metastatic phenotype. *Mechanisms of Ageing and Development*, **2013**, 134, 118-29	5.6	7
44	Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. *Proteomics*, **2013**, 13, 1595-607	4.8	22
43	Brain neoplasms and coagulation. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 881-95	5.3	27
42	Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. *Frontiers in Pharmacology*, **2013**, 4, 21	5.6	129
41	Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. *Blood*, **2012**, 119, 5543-52	2.2	148
40	Genetic pathways linking hemostasis and cancer. *Thrombosis Research*, **2012**, 129 Suppl 1, S22-9	8.2	34
39	Extracellular vesicles--vehicles that spread cancer genes. *BioEssays*, **2012**, 34, 489-97	4.1	130
38	VEGF-D(ilated) lymphatics as gateways to metastasis. *Cancer Cell*, **2012**, 21, 139-40	24.3	2
37	Oncogenic extracellular vesicles in brain tumor progression. *Frontiers in Physiology*, **2012**, 3, 294	4.6	86

36	Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. *Journal of Biological Chemistry*, **2012**, 287, 43565-72	5.4	111
35	Age-related properties of the tumour vasculature in renal cell carcinoma. *BJU International*, **2011**, 107, 416-24	5.6	19
34	Microvesicles as mediators of intercellular communication in cancer--the emerging science of cellular ŚdebrisŚ *Seminars in Immunopathology*, **2011**, 33, 455-67	12	391
33	Microparticles in cancer. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 888-906	5.3	228
32	New technologies for the detection of circulating tumour cells. *British Medical Bulletin*, **2010**, 94, 49-64	5.4	89
31	Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. *Thrombosis Research*, **2010**, 126, e6-10	8.2	20
30	Role of the tissue factor pathway in the biology of tumor initiating cells. *Thrombosis Research*, **2010**, 125 Suppl 2, S44-50	8.2	36
29	Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. *Blood*, **2010**, 116, 815-8	2.2	110
28	RAS Oncogenes and Tumor-Vascular Interface **2010**, 133-165		1
27	Angiogenesis and Lymphangiogenesis in Colon Cancer Metastasis. *Cancer Metastasis - Biology and Treatment*, **2010**, 243-287		1
26	Microvesicles: messengers and mediators of tumor progression. *Cell Cycle*, **2009**, 8, 2014-8	4.7	339
25	Tissue factor and cancer stem cells: is there a linkage?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 2005-14	9.4	33
24	Oncogene-Driven Hemostatic Changes in Cancer. *Cancer Investigation*, **2009**, 27, 28-35	2.1	2
23	Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3794-9	11.5	531
22	Tissue factor in tumour progression. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 71-83	4.2	48
21	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. *Nature Cell Biology*, **2008**, 10, 619-24	23.4	1405
20	Contribution of host-derived tissue factor to tumor neovascularization. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 1975-81	9.4	71
19	Diverse roles of tissue factor-expressing cell subsets in tumor progression. *Seminars in Thrombosis and Hemostasis*, **2008**, 34, 170-81	5.3	20

18	Tissue factor in cancer. *Current Opinion in Hematology*, **2008**, 15, 522-8	3.3	43
17	Vascular determinants of cancer stem cell dormancy--do age and coagulation system play a role?. *Apmis*, **2008**, 116, 660-76	3.4	23
16	Tissue factor and cancer. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2008**, 36, 160-76		45
15	Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. *American Journal of Pathology*, **2007**, 171, 1342-51	5.8	29
14	The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. *Thrombosis Research*, **2007**, 120 Suppl 2, S82-91	8.2	38
13	Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. *Seminars in Thrombosis and Hemostasis*, **2006**, 32, 54-70	5.3	99
12	Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. *Cancer Research*, **2006**, 66, 10643-6	10.1	124
11	Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis?. *Medical Hypotheses*, **2006**, 66, 601-4	3.8	31
10	Regulation of tissue factor and angiogenesis-related genes by changes in cell shape. *Biochemical and Biophysical Research Communications*, **2005**, 337, 1267-75	3.4	13
9	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. *Cancer Research*, **2005**, 65, 8878-86	10.1	52
8	Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. *Seminars in Thrombosis and Hemostasis*, **2004**, 30, 21-30	5.3	46
7	Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". *Seminars in Cancer Biology*, **2004**, 14, 93-104	12.7	58
6	Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. *EMBO Journal*, **2003**, 22, 4091-102	13	51
5	Oncogenes and angiogenesis: signaling three-dimensional tumor growth. *Journal of Investigative Dermatology Symposium Proceedings*, **2000**, 5, 24-33	1.1	159
4	Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. *Cancer and Metastasis Reviews*, **2000**, 19, 93-6	9.6	38
3	Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. *Oncogene*, **1999**, 18, 1023-32	9.2	68
2	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. *Angiogenesis*, **1998**, 2, 203-17	10.6	25
1	A reference map of the human protein interactome		13